Qtron Investments LLC Invests $739,000 in Insulet Co. (NASDAQ:PODD)

Qtron Investments LLC bought a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,830 shares of the medical instruments supplier's stock, valued at approximately $739,000.

A number of other hedge funds also recently bought and sold shares of the company. Baillie Gifford & Co. increased its stake in Insulet by 3.5% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock worth $614,998,000 after purchasing an additional 79,982 shares during the period. Geode Capital Management LLC grew its holdings in shares of Insulet by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock worth $463,347,000 after purchasing an additional 40,566 shares during the last quarter. Norges Bank purchased a new position in shares of Insulet in the fourth quarter worth $248,806,000. Artisan Partners Limited Partnership raised its holdings in Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after buying an additional 149,524 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Insulet by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier's stock valued at $168,902,000 after buying an additional 10,694 shares during the period.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

Remove Ads

Insulet Stock Up 0.4 %

NASDAQ:PODD traded up $0.95 on Tuesday, reaching $256.42. 542,491 shares of the stock traded hands, compared to its average volume of 717,169. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $18.01 billion, a price-to-earnings ratio of 44.29, a PEG ratio of 3.62 and a beta of 1.30. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company's fifty day simple moving average is $265.46 and its 200 day simple moving average is $260.69.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PODD. StockNews.com cut Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Piper Sandler raised their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Stifel Nicolaus boosted their price target on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Canaccord Genuity Group lifted their price objective on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, TD Cowen increased their target price on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and a consensus price target of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.